Rise
in the incidence of rare diseases and increase in the demand for
non-therapeutic applications have fueled the growth of global albumin market.
Moreover, mounting predilection for recombinant albumin for the treatment of
burns, shock and blood loss spur the growth of the market. On the other hand,
stringent government norms and certain threats related to albumin have happened
to check the market growth to some extent.
However, untapped opportunities in
developing economies and development of cost-efficient therapeutics have
created multiple opportunities in the segment.
The
key players analyzed in the report include
China Biologic Products Inc.
Octapharma AG
CSL Limited
Thermo Fisher Scientific
Baxter International Inc. Shire Plc
Albumedix Ltd.
Grifols S.A.
Ventria Bioscience
Merck KGaA.
They
have adopted a number of strategies such as group effort, partnerships, mergers
& acquisitions, developments, joint ventures, and others to attain a strong
footholdhold in the industry.
By
product, Human serum albumin segment contributed to nearly three-fourths share
of the total market in 2017. Based on application, the theraputic segment
accounted for nearly half of the total market share in 2017 and would retain
its top status till 2023. By region, North America accounted for more than
one-third of the total market share in 2017 and is expected to dominate during
the forecast period. This is due to rising adoption of recombinant albumin
products, high-end healthcare infrastructure, and prevalence of trauma, shocks,
burns, hepatic surgeries and liver related disorders in the region.
Rise
in the incidence of rare diseases and increase in the demand for
non-therapeutic applications have fueled the growth of global albumin market.
Moreover, mounting predilection for recombinant albumin for the treatment of
burns, shock and blood loss spur the growth of the market. On the other hand,
stringent government norms and certain threats related to albumin have happened
to check the market growth to some extent. However, untapped opportunities in
developing economies and development of cost-efficient therapeutics have
created multiple opportunities in the segment.
The
key players analyzed in the report include
China Biologic Products Inc.
Octapharma AG
CSL Limited
Thermo Fisher Scientific
Baxter International Inc. Shire Plc
Albumedix Ltd.
Grifols S.A.
Ventria Bioscience
Merck KGaA.
They
have adopted a number of strategies such as group effort, partnerships, mergers
& acquisitions, developments, joint ventures, and others to attain a strong
footholdhold in the industry.
By
product, Human serum albumin segment contributed to nearly three-fourths share
of the total market in 2017. Based on application, the theraputic segment
accounted for nearly half of the total market share in 2017 and would retain
its top status till 2023. By region, North America accounted for more than
one-third of the total market share in 2017 and is expected to dominate during
the forecast period. This is due to rising adoption of recombinant albumin
products, high-end healthcare infrastructure, and prevalence of trauma, shocks,
burns, hepatic surgeries and liver related disorders in the region.
No comments:
Post a Comment